SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-047138
Filing Date
2023-09-08
Accepted
2023-09-08 08:00:11
Documents
14
Period of Report
2023-09-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20230906.htm   iXBRL 8-K 54428
2 EX-10.1 rare-ex10_1.htm EX-10.1 16583
3 GRAPHIC img127468354_0.jpg GRAPHIC 19924
  Complete submission text file 0000950170-23-047138.txt   214068

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rare-20230906.xsd EX-101.SCH 2475
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rare-20230906_lab.xml EX-101.LAB 12806
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rare-20230906_pre.xml EX-101.PRE 9457
8 EXTRACTED XBRL INSTANCE DOCUMENT rare-20230906_htm.xml XML 4516
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 231243696
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences